Virios Q3 net loss narrows to $1.2M; secures FDA guidance for IMC-1 Phase 3

Dogwood Therapeutics, Inc.

2023-Q3 EPS reported -$0.23

Net loss $1.2M ($0.06/share) vs $2.6M ($0.28/share) in Q3 2022; cash $4.8M.
R&D expenses fell to $0.4M from $1.6M on lower clinical trial costs.
FDA guidance secured for IMC-1 Phase 3 in fibromyalgia; partnership discussions underway.
Briefing materials submitted to FDA for IMC-2 IND to treat Long-COVID.
Cash runway expected into Q3 2024 through expense management.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dogwood Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $1.2 million, or $0.06 basic and diluted net loss per share, EPS $0.06 basic and diluted net loss per share.

Period: the third quarter ended September 30, 2023
Net income: $1.2 million, or $0.06 basic and diluted net loss per share
EPS: $0.06 basic and diluted net loss per share
Result: reported results

Exact text from the filing

On November 13, 2023, Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.